Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The use of adeno-associated virus (AAV) as a gene therapy vector has been approved recently for clinical use and has demonstrated efficacy in a growing number of clinical trials. However, the safety of AAV as a vector has been challenged by a single study that documented hepatocellular carcinoma (HCC) after AAV gene delivery in mice. Most studies have not noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is an association between AAV and HCC is controversial. Here, we performed a comprehensive study of HCC in a large number of mice following therapeutic AAV gene delivery. Using a sensitive high-throughput integration site-capture technique and global expressional analysis, we found that AAV integration into the RNA imprinted and accumulated in nucleus (Rian) locus, and the resulting overexpression of proximal microRNAs and retrotransposon-like 1 (Rtl1) were associated with HCC. In addition, we demonstrated that the AAV vector dose, enhancer/promoter selection, and the timing of gene delivery are all critical factors for determining HCC incidence after AAV gene delivery. Together, our results define aspects of AAV-mediated gene therapy that influence genotoxicity and suggest that these features should be considered for design of both safer AAV vectors and gene therapy studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [179]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“GCGCGCTCGCTCG-3′) were trimmed by cutadapt (57).”
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“To investigate this possibility, we developed a vector, AAV8-hAAT-synMUT, modeled on a AAV vector that had been administered to human subjects with hemophilia and did not cause genotoxicity in mice (13, 33).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In fact, there are multiple human AAV gene therapy trials around the world that have been completed, are accruing participants, or are in preparation (4), and recent studies using AAV to treat 3 genetic disorders have been regarded as successful (5–8).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The most relevant example is the failure of animal studies to predict the increased risk for the development of leukemia after retroviral gene therapy for X-linked severe combined immunity deficiency (45).”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“…the use of a more hepatotrophic serotype, such as AAV8 compared with AAV2, led to an increase in the rate of HCC. Additionally, the use of distinct capsids to pseudotype AAV vectors (48), such as serotypes 8 and 9, confers distinct patterns of tissue troph-ism in wild-type and disease states (49).”
Ensembl BioMarts: a hub for data retrieval across taxonomic space
Kinsella, R. J., Kahari, A., Haider, S., Zamora, J., Proctor, G., Spudich, G., Almeida-King, J., Staines, D., Derwent, P., Kerhornou, A., et al. (2011) · Database · doi:10.1093/database/bar030 · Cited by 1,437
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159 · cited 1×
“In fact, there are multiple human AAV gene therapy trials around the world that have been completed, are accruing participants, or are in preparation (4), and recent studies using AAV to treat 3 genetic disorders have been regarded as successful (5–8).”
BamTools: a C++ API and toolkit for analyzing and managing BAM files
Barnett, D. W., Garrison, E. K., Quinlan, A. R., Strömberg, M. P., & Marth, G. T. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr174 · Cited by 1,039
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 1×
“AAVs have therefore emerged as promising vectors for gene delivery (2) and have been extensively studied in small-and large-animal models for preclinical efficacy and safety (3).”
Flicek, P., Ahmed, I., Amode, M. R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fairley, S., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1236 · Cited by 869 · cited 1×
“Integra-tions were annotated using Mus musculus genes (Genome Reference Consortium Mouse Build 38 patch release 1) from Ensembl Genes 70, downloaded from BioMart (59, 60).”
Site-specific integration by adeno-associated virus.
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., & Berns, K. I. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2211 · Cited by 868 · cited 9×
“The following primers were used for the first round of PCR: AAV ITR primer, 5 ′ -GGAGTTGGC- CACTCCCTCTCTG-3 ′ , and linker primer, 5 ′ -GTAATACGACT- CACTATAGGGCACGCGTG-3 ′ .”
InfluentialSite-specific integration by adeno-associated virus.
Linden, R. M., Ward, P., Giraud, C., Winocour, E., & Berns, K. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11288 · Cited by 805
AAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 6×
“In addition to the upregulation of proximal microRNAs at the Rian locus in the AAV HCCs, we identified a gene, Rtl1 , with increased expression that had not been noted previously by Donsante et al. (10).”
InfluentialSelf-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 1×
“Self-complementary AAV vectors are claimed to exhibit superior in vivo efficacy compared with that of single-stranded vectors (47), but whether the self-complementary genome configuration influences integration preference compared with an equivalent single-stranded AAV vector is unknown and worthy of comparative study.”
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465 · cited 2×
“AAVs have therefore emerged as promising vectors for gene delivery (2) and have been extensively studied in small-and large-animal models for preclinical efficacy and safety (3).”
Ylä-Herttuala, S. (2012) · Molecular Therapy · doi:10.1038/mt.2012.194 · Cited by 463 · cited 4×
“Using a murine model of β -glucuronidase deficiency (mucopolysaccharidosis type VII), Donsante et al. documented an increased rate of HCC formation in mice treated with a therapeutic AAV vector in the neonatal period (10, 11).”
InfluentialGaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
AAV serotype 2 vectors preferentially integrate into active genes in mice
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A. (2003) · Nature Genetics · doi:10.1038/ng1179 · Cited by 392 · cited 3×
“While AAV is known to have a preference to integrate into actively transcribed genes (30), we are unaware of any reports that correlate higher tissue-specific gene expression with increased AAV integration frequency.”
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 1×
“Other capsid-specific properties may influence genotoxicity, such as subcellular localization (50), uncoating kinetics (51), and perhaps even transcription of the input genome (52).”
Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors
Donsante, A., Vogler, C., Muzyczka, N., Crawford, J., Barker, J., Flotte, T., Campbell-Thompson, M., Daly, T., & Sands, M. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301541 · Cited by 319 · cited 3×
“documented an increased rate of HCC formation in mice treated with a therapeutic AAV vector in the neonatal period (10, 11).”
Promoterless gene targeting without nucleases ameliorates haemophilia B in mice
Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P. N., Spector, L. P., Porteus, M. H., Gaensler, K. M., et al. (2015) · Nature · doi:10.1038/nature13864 · Cited by 257
Themis, M., Waddington, S. N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., Gregory, L. G., Nivsarkar, M., Themis, M., Holder, M. V., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.358 · Cited by 243 · cited 1×
“The orientation of the vector integration events was not determined and therefore remains hypothetical. jci.org Volume 125 Number 2 February 2015 locus, which is highly susceptible to insertional mutagenesis (32, 41, 42), is vulnerable to AAV integrations (43, 44).”
Assessing the potential for AAV vector genotoxicity in a murine model
Li, H., Malani, N., Hamilton, S. R., Schlachterman, A., Bussadori, G., Edmonson, S. E., Shah, R., Arruda, V. R., Mingozzi, F., Fraser Wright, J., et al. (2011) · Blood · doi:10.1182/blood-2010-08-302729 · Cited by 236
Jeganathan, K., Malureanu, L., Baker, D. J., Abraham, S. C., & van Deursen, J. M. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200706015 · Cited by 221
Spontaneous Lesions in Aging FVB/N Mice
Mahler, J. F., Stokes, W., Mann, P. C., Takaoka, M., & Maronpot, R. R. (1996) · Toxicologic Pathology · doi:10.1177/019262339602400606 · Cited by 217 · cited 1×
“The incidence of spontaneous hepatic tumors arising in FVB/N mice appears similar, with approximately 20% of male mice ( n = 29) developing hepatic tumors by the age of 24 months (37).”
Mitochondrial dysfunction in mut methylmalonic acidemia
Chandler, R. J., Zerfas, P. M., Shanske, S., Sloan, J., Hoffmann, V., DiMauro, S., & Venditti, C. P. (2009) · The FASEB Journal · doi:10.1096/fj.08-121848 · Cited by 198 · cited 8×
“Our previous studies using neonatal AAV gene delivery to treat mice with methylmalonic acidemia (MMA) provided a large set of homogenously treated animals that were used to interrogate the possible genotoxicity of AAV gene therapy and explore mechanisms of carcinogenesis.”
InfluentialSelf-citationDupuy, A. J., Rogers, L. M., Kim, J., Nannapaneni, K., Starr, T. K., Liu, P., Largaespada, D. A., Scheetz, T. E., Jenkins, N. A., & Copeland, N. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1135 · Cited by 168 · cited 2×
“The orientation of the vector integration events was not determined and therefore remains hypothetical. jci.org Volume 125 Number 2 February 2015 locus, which is highly susceptible to insertional mutagenesis (32, 41, 42), is vulnerable to AAV integrations (43, 44).”
Luk, J. M., Burchard, J., Zhang, C., Liu, A. M., Wong, K. F., Shek, F. H., Lee, N. P. Y., Fan, S. T., Poon, R. T. P., Ivanovska, I. L., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229831 · Cited by 156
Analysis of Tumors Arising in Male B6C3F1 Mice with and without AAV Vector Delivery to Liver
Bell, P., Moscioni, A. D., McCarter, R. J., Wu, D., Gao, G., Hoang, A., Sanmiguel, J. C., Sun, X., Wivel, N. A., Raper, S. E., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.008 · Cited by 149
No Evidence for Tumorigenesis of AAV Vectors in a Large-Scale Study in Mice
Bell, P., Wang, L., Lebherz, C., Flieder, D. B., Bove, M. S., Wu, D., Gao, G. P., Wilson, J. M., & Wivel, N. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.020 · Cited by 135 · cited 2×
“Subsequently, several larger independent investigations designed to investigate AAV-mediated genotoxicity in mice were unable to document an increased risk of tumorigenesis (12, 13), but these studies failed to replicate key experimental variables, such as the timing of viral administration, vector configurations, dos…”
Bantel-Schaal, U., Hub, B., & Kartenbeck, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2340-2349.2002 · Cited by 129 · cited 1×
“Other capsid-specific properties may influence genotoxicity, such as subcellular localization (50), uncoating kinetics (51), and perhaps even transcription of the input genome (52).”
A large-scale zebrafish gene knockout resource for the genome-wide study of gene function
Varshney, G. K., Lu, J., Gildea, D. E., Huang, H., Pei, W., Yang, Z., Huang, S. C., Schoenfeld, D., Pho, N. H., Casero, D., et al. (2013) · Genome Research · doi:10.1101/gr.151464.112 · Cited by 115 · cited 1×
“Samples were prepared for high-throughput sequencing as previously described (54), with the following modifications.”
Self-citationMLV integration site selection is driven by strong enhancers and active promoters
LaFave, M. C., Varshney, G. K., Gildea, D. E., Wolfsberg, T. G., Baxevanis, A. D., & Burgess, S. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1399 · Cited by 114 · cited 4×
“…the use of LM-PCR with 3 parallel frequent-cut-ting enzyme digests ( MseI , BfaI , and Csp6I ) has provided an improved recovery, fewer artifacts, and lower amplification distortion in studies using this method to capture retroviral integrations (29) and was therefore adapted to the study of AAV.”
InfluentialSelf-citationInduction of hepatocellular carcinoma by in vivo gene targeting
Wang, P.-R., Xu, M., Toffanin, S., Li, Y., Llovet, J. M., & Russell, D. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117032109 · Cited by 105 · cited 3×
“Our results (Figure 5A and Table 1) and those previously reported document HCCs in mice after receiving AAV vectors carrying the TBG and CBA enhancer promoters (11, 17, 32) and not in mice after receiving AAVs configured with other enhancer promoters (13).”
Lentiviral vector–based insertional mutagenesis identifies genes associated with liver cancer
Ranzani, M., Cesana, D., Bartholomae, C. C., Sanvito, F., Pala, M., Benedicenti, F., Gallina, P., Sergi, L. S., Merella, S., Bulfone, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2331 · Cited by 98
Rosas, L. E., Grieves, J. L., Zaraspe, K., La Perle, K. M., Fu, H., & McCarty, D. M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.197 · Cited by 96 · cited 3×
“In contrast to other preclinical studies (16, 17), the untreated control heterozygous mice used in this work did not display a strain tendency toward the development of HCC (Figure 1B and Table 1).”
InfluentialBiosafety of Recombinant Adeno-associated Virus Vectors
Dismuke, D., Tenenbaum, L., & Samulski, R. (2014) · Current Gene Therapy · doi:10.2174/15665232113136660007 · Cited by 91 · cited 1×
“org Volume 125 Number 2 February 2015 Introduction Adeno-associated virus (AAV) is regarded as nonpathogenic (1) and, when configured for gene therapy applications, is devoid of an intrinsic capacity to replicate and integrate.”
Riordan, J. D., Keng, V. W., Tschida, B. R., Scheetz, T. E., Bell, J. B., Podetz-Pedersen, K. M., Moser, C. D., Copeland, N. G., Jenkins, N. A., Roberts, L. R., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003441 · Cited by 91
Salganik, M., Aydemir, F., Nam, H.-J., McKenna, R., Agbandje-McKenna, M., & Muzyczka, N. (2014) · Journal of Virology · doi:10.1128/jvi.02093-13 · Cited by 73
Hatada, I., Morita, S., Obata, Y., Sotomaru, Y., Shimoda, M., & Kono, T. (2001) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a002971 · Cited by 72 · cited 1×
“This is a complex genomic region that encodes numerous regulatory RNAs, including microRNAs (miRNAs), snoRNAs, and lincRNA (23).”
Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle
Chandler, R. J., Sloan, J., Fu, H., Tsai, M., Stabler, S., Allen, R., Kaestner, K. H., Kazazian, H. H., & Venditti, C. P. (2007) · BMC Medical Genetics · doi:10.1186/1471-2350-8-64 · Cited by 63
Self-citationCarrillo-Carrasco, N., Chandler, R. J., Chandrasekaran, S., & Venditti, C. P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.008 · Cited by 54
Self-citationAAV Vectors, Insertional Mutagenesis, and Cancer
Russell, D. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300299 · Cited by 53
Chandler, R. J., & Venditti, C. P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.247 · Cited by 52
Self-citationAAV vectors and tumorigenicity
Kay, M. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1111 · Cited by 50 · cited 1×
“Therefore, an association between AAV and HCC in the setting of therapeutic gene delivery has remained uncertain (15–21) and mechanism(s) of AAV-mediated HCC have remained unresolved (15, 19, 22).”
Zhong, L., Malani, N., Li, M., Brady, T., Xie, J., Bell, P., Li, S., Jones, H., Wilson, J. M., Flotte, T. R., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.112 · Cited by 49
Chen, Y. H., Claflin, K., Geoghegan, J. C., & Davidson, B. L. (2012) · Molecular Therapy · doi:10.1038/mt.2012.100 · Cited by 46
Hüser, D., Gogol-Döring, A., Chen, W., & Heilbronn, R. (2014) · Journal of Virology · doi:10.1128/jvi.01356-14 · Cited by 43 · cited 1×
“It is noteworthy that the Afp and Alb genes are tightly linked, which suggests that open chromatin, in the setting of active transcription and the vector itself, presents interacting factors that influence where an AAV vector integrates (39).”
rAAV-Mediated Tumorigenesis: Still Unresolved After an AAV Assault
Valdmanis, P. N., Lisowski, L., & Kay, M. A. (2012) · Molecular Therapy · doi:10.1038/mt.2012.220 · Cited by 36
Abnormal Hepatocellular Mitochondria in Methylmalonic Acidemia
Wilnai, Y., Enns, G. M., Niemi, A.-K., Higgins, J., & Vogel, H. (2014) · Ultrastructural Pathology · doi:10.3109/01913123.2014.921657 · Cited by 34 · cited 1×
“Although hepatic perturbations have been well documented in mice and patients with MMA (34, 35), neither the disease state nor carrier status for MMA is recognized to confer an increased risk to develop HCC.”
Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery
Senac, J. S., Chandler, R. J., Sysol, J. R., Li, L., & Venditti, C. P. (2011) · Gene Therapy · doi:10.1038/gt.2011.108 · Cited by 33
Self-citationChandler, R., & Venditti, C. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.09.019 · Cited by 27
Self-citationNowrouzi, A., Cheung, W., Li, T., Zhang, X., Arens, A., Paruzynski, A., Waddington, S. N., Osejindu, E., Reja, S., Kalle, C. V., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.224 · Cited by 24 · cited 1×
“org Volume 125 Number 2 February 2015 locus, which is highly susceptible to insertional mutagenesis (32, 41, 42), is vulnerable to AAV integrations (43, 44).”
No tumour-initiating risk associated with scAAV transduction in newborn rat liver
Gauttier, V., Pichard, V., Aubert, D., Kaeppel, C., Schmidt, M., Ferry, N., & Conchon, S. (2013) · Gene Therapy · doi:10.1038/gt.2013.7 · Cited by 23
Li, C., Yu, S., Zhong, X., Wu, J., & Li, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031292 · Cited by 21 · cited 1×
“…of Rian integrations in adult mice treated with AAV could be explained by the fact that Rian is expressed at higher levels in the livers of neonatal mice compared with that in those of the adult mice (40) and that AAV demonstrates a preference to integrate into actively transcribed genes (30).”
Age-related Incidence of Spontaneous Tumors in SPF C57BL/6 and BDF1 Mice
Nakamura, K., Kuramoto, K., SHIBASAKI, K., Shumiya, S., & Ohtsubo, K. (1992) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim1978.41.3_279 · Cited by 18
Vector-related Tumorigenesis Not Found in Ornithine Transcarbamylase-deficient Mice
Koeberl, D. D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.011 · Cited by 5
Montini, E. (2011) · Blood · doi:10.1182/blood-2011-02-321984 · Cited by 5
Research works printed but not linked: 2
- Nakamura, 1992, Jikken Dobutsu., 41, 279
- Martin, 2011, EMBnetJ., 17
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“This integration leads to the dysregulation of genes (Rlt1 and various microRNAs) flanking the insertion site promoting HCC.(155) Notably, in humans, the Rian locus is not present, although upregulation of delta-like homolog 1-deiodinase type 3 (DLK1-DIO3) locus, the human ortholog of the Rian microRNA locus, has been…”
BackgroundInfluentialHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Metadata
- Authors
- Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., & Venditti, C. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-01-20
- Volume
- 125
- Issue
- 2
- Pages
- 870-880
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4319425
- OpenAlex
- W2133112334
- Cited by
- 403
- References
- 63
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 40 · 2023: 38 · 2022: 36 · 2021: 32 · 2020: 45 · 2019: 30 · 2018: 26 · 2017: 32 · 2016: 31 · 2015: 22
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- adeno-associated virus, gene therapy vectors, hepatocellular carcinoma, genotoxicity, AAV integration, microRNA overexpression, RTL1, vector dose
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Mutant Strains, Pregnancy Proteins, Transduction, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.